New Jersey · 17274

Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm in New Jersey

New Jersey Medicare Avg
$190.04
17% above national avg
National Medicare Avg
$163.08
All states combined
Billed Charge (NJ)
$423.40
What providers submit
Est. Commercial (NJ)
$646.83
National avg: $473.57
Est. Cash / Self-Pay (NJ)
$306.68
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

59
Services in NJ
36
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in New Jersey

Provider Medicare Services
Karakashian, Gary M.D. $193.22 15

New Jersey Pricing in Context

In New Jersey, CPT code 17274 (Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm) carries an average Medicare payment of $190.04 — 17% above the national benchmark of $163.08. 36 providers across the state submitted claims for this procedure in 2023, performing 59 total services. Individual payments in NJ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in New Jersey is $423.40, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because New Jersey sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Skin/Integumentary Surgery procedures, the estimated commercial insurance price in New Jersey lands near $646.83, with self-pay cash prices typically around $306.68. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm cost in New Jersey?

The average Medicare payment for Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm in New Jersey is $190.04, which is 17% above the national average of $163.08. Providers in NJ typically bill $423.40 for this procedure.

What does Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm cost with insurance in New Jersey?

With commercial insurance in New Jersey, Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm costs an estimated $646.83. Without insurance, the estimated cash price is $306.68. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm in New Jersey?

36 providers in New Jersey billed Medicare for Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm in 2023, performing 59 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm cheaper in New Jersey than the national average?

No — Destruction Of Cancer Skin Growth Of Scalp, Neck, Hands, Feet, Or Genitals, 3.1-4.0 Cm costs 17% above the national average in New Jersey. The state average Medicare payment is $190.04 compared to $163.08 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial